N/A
Manufactured by Aurobindo Pharma Limited
3,283 FDA adverse event reports analyzed
Last updated: 2026-04-15
PIOGLITAZONE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for PIOGLITAZONE HYDROCHLORIDE include DYSPNOEA, DRUG INEFFECTIVE, NAUSEA, PAIN IN EXTREMITY, HYPOGLYCAEMIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PIOGLITAZONE HYDROCHLORIDE.
Out of 1,199 classified reports for PIOGLITAZONE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 3,283 FDA FAERS reports that mention PIOGLITAZONE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, DRUG INEFFECTIVE, NAUSEA, PAIN IN EXTREMITY, HYPOGLYCAEMIA, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with PIOGLITAZONE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.